Medical Device EU Import and Distribution

Medical Device EU Import and Distribution

The European Union’s Medical Device Regulation (MDR 2017/745) and In Vitro Diagnostic Regulation (IVDR 2017/746) establish stringent compliance obligations for all economic operators involved in the medical device supply chain. Article 16 of both regulations specifically delineates the regulatory responsibilities of importers and distributors engaging in relabeling and repackaging activities.

Given that these modifications can significantly affect regulatory compliance, importers and distributors must obtain Article 16 certification from a notified body (NB) to ensure that their quality management system (QMS) aligns with EU regulatory requirements. This document provides an in-depth examination of the scope, obligations, qualifying activities, and certification process under Article 16.

Guidance on Article 16 Compliance: MDCG 2021-23

The MDCG 2021-23 guidance document provides regulatory clarification on how economic operators, including importers and distributors, must comply with Article 16 of MDR and IVDR. This guidance defines best practices for ensuring compliance when conducting relabeling and repackaging activities, with a focus on quality system requirements, traceability measures, and risk management protocols.

Furthermore, the guidance specifies the documentation requirements necessary to demonstrate that relabeling and repackaging activities do not compromise the device’s original integrity and performance. Additionally, MDCG 2021-23 mandates that importers and distributors implement post-market surveillance activities to track any modifications made to a device throughout its distribution lifecycle.

Scope and Compliance Obligations under Article 16

Article 16 of MDR and IVDR outlines specific regulatory requirements for importers and distributors performing the following activities:

• Translation of labeling, instructions for use (IFUs), or other documentation to meet national language requirements.
• Repackaging of medical devices to ensure compliance with local packaging regulations, including the subdivision of bulk packaging into smaller units.
• Addition of supplementary labeling information to fulfill regulatory requirements while maintaining device integrity.

Although these activities do not alter the device’s intended purpose or fundamental nature, they introduce compliance risks that necessitate QMS oversight. Consequently, importers and distributors engaging in relabeling and repackaging must obtain Article 16 certification from a notified body to demonstrate adherence to EU regulatory and safety standards.

Determining the Necessity for Article 16 Certification

Not all importers and distributors are required to obtain Article 16 certification. The certification is specifically applicable to companies that:

• Modify medical device packaging or labeling post-market placement.
• Translate IFUs or labeling to meet national language requirements.
• Repackage bulk medical devices into smaller units for market distribution.
• Perform any of the above activities independently, outside the direct control of the legal manufacturer.

Conversely, companies are exempt from Article 16 certification if:

• They operate within the manufacturer’s ISO 13485-certified QMS framework.
• They distribute devices without modifying labeling or packaging.
• They are healthcare institutions repackaging devices solely for internal use (e.g., hospital in-house supply management).

Essential Regulatory Requirements for Article 16 Certification

To obtain Article 16 certification, importers and distributors must establish a comprehensive QMS that meets MDR and IVDR requirements. The following regulatory elements must be addressed:

1. Documentation and Record-Keeping:

• Maintain detailed records of all relabeling and repackaging activities, including batch/lot numbers, modification dates, and responsible personnel.
• Retain records for at least 10 years post-market placement (15 years for implantable devices) in compliance with MDR/IVDR.
• Implement document control and version tracking mechanisms to ensure regulatory document accuracy and approval workflow adherence.

2. Supplier and Subcontractor Management:

• Establish supplier qualification processes to ensure subcontractor compliance with ISO 13485 and MDR/IVDR.
• Conduct supplier audits and implement risk assessment frameworks to manage regulatory compliance risks.
• Define quality agreements with subcontractors to establish compliance responsibilities.

3. Facility and Resource Management:

• Ensure relabeling and repackaging facilities meet Good Manufacturing Practices (GMP) and controlled environmental conditions.
• Implement training programs for staff handling repackaging activities.
• For sterile medical devices, maintain ISO 14644 cleanroom classification standards.

4. Corrective and Preventive Actions (CAPA) and Post-Market Surveillance:

• Establish a system for non-conformance reporting (NCR) and root cause analysis (RCA) for compliance deviations.
• Implement a recall response plan and maintain open communication with legal manufacturers to address field safety corrective actions (FSCAs).

5. Traceability and Labeling Compliance:

• Implement Unique Device Identification (UDI) tracking to maintain compliance with MDR/IVDR traceability mandates.
• Conduct label verification checks to ensure compliance with manufacturer specifications and regulatory requirements.
• Utilize electronic batch records (EBRs) for traceability and recall efficiency.

Certification Process for Article 16 Compliance

The certification process for Article 16 compliance involves the following five steps:

1. Initial Inquiry & Application: Submit an inquiry to a notified body and undergo a pre-application review.
2. Quality System Assessment: The notified body audits the importer’s/distributor’s QMS and regulatory documentation.
3. Audit & Compliance Verification: On-site audits are conducted to validate labeling, packaging, and document control processes.
4. Certification Issuance: Upon successful completion, an Article 16 certificate is granted, valid for three years with annual surveillance audits.
5. Ongoing Compliance & Renewal: Annual audits and full recertification assessments are required to maintain compliance.

Common Compliance Challenges and Regulatory Risks

Despite clear regulatory requirements, economic operators often face challenges in achieving Article 16 certification, including:

• Deficient Documentation: Insufficient record-keeping can result in non-compliance findings during audits. Companies should implement electronic documentation systems with automated version tracking.
• Supply Chain Complexity: Reliance on subcontractors may create regulatory risks if suppliers fail to meet MDR/IVDR requirements. Establishing rigorous supplier qualification procedures and legally binding agreements is essential.
• Regulatory Misinterpretation: Failure to distinguish between manufacturer-approved modifications and those requiring Article 16 certification can lead to regulatory violations. Importers and distributors should engage regulatory experts to clarify compliance obligations.
• Delayed Notifications: Failure to notify competent authorities and legal manufacturers at least 28 days before placing relabeled/repackaged devices on the market can result in penalties. Automated compliance reminders can mitigate this risk.

Conclusion

Under Article 16(2) of MDR and IVDR, importers and distributors engaging in relabeling or repackaging must obtain an Article 16(4) certificate from the competent authority of the EU Member State in which the modified device will be marketed. Companies applying for this certification must work with a notified body designated for the relevant device category and implement a QMS that adheres to Article 16(3) requirements.

Ensuring compliance with MDR and IVDR regulations enables importers and distributors to:

• Maintain uninterrupted access to the EU medical device market.
• Avoid regulatory sanctions and product recalls.
• Strengthen relationships with legal manufacturers and regulatory authorities.
• Enhance post-market surveillance capabilities.

To facilitate compliance, economic operators should:

• Engage with a notified body early to clarify certification requirements.
• Invest in QMS enhancements for improved traceability and compliance.
• Conduct internal audits before formal notified body assessments.
• Stay informed of evolving EU regulatory requirements.

Article 16 certification is a critical regulatory mechanism to safeguard the integrity, safety, and quality of relabeled and repackaged medical devices in the EU. Companies must proactively ensure compliance to facilitate smooth market entry and long-term regulatory success.

Topics: #healthcare #lifeSciences #medicaldevices #medtech #medicaltechnology #MedSysCon #import #distribution

For further information please get in touch with us:

www.medsyscon.com/en

info@medsyscon.com

+49-176-57694801